Nasal Photodisinfection Therapy Decreases SARS-CoV-2 Impact

The first randomized, placebo-controlled, single-blind clinical study of Ondine Biomedical Inc.'s Steriwave™ nasal photodisinfection was published in Frontiers in Cellular and Infection Microbiology.

This limited study, announced on January 31, 2023, met its primary endpoint, with a highly significant decrease in viral infectivity recorded as early as two days after treatment (p<0.0001).

Steriwave therapy also significantly improved the immune-protective status of treated patients, as measured by PCR testing one week after treatment (over six times fewer PCR-positive patients compared to controls).

The study was conducted at the Clínica Universidad de Navarra in Spain during the sixth Omicron outbreak in late 2021 and early 2022. Over 90% of the patients recruited into the study were fully vaccinated.

Ondine is seeking to offer a therapeutic approach to those patients who test positive but are not yet symptomatic or to those individuals who have had known exposure to a COVID-19 patient.

Currently, there are no U.S. FDA-approved approaches for killing the coronavirus while it is still located in the nose and throat.

Ondine Biomedical Inc. is a Canadian life sciences company innovating in the field of photodisinfection therapies.